BOC International Holdings
VC Fund
Central, Hong Kong
BOC International Holdings is a VC fund in Central focused on Manufacturing and Medical. BOC International Holdings Limited, which specializes in investment banking, is a wholly owned subsidiary of Bank of China Ltd. BOCI has created an organizational framework with an effective integrated management system. It has subsidiaries in New York, London, Hong Kong and Singapore, and a sales network covering most major Chinese cities such asBeijing, Shanghai, Guangzhou and Chongqing. With a team of seasoned financial professionals, a broad institutional and retail sales network and a global management operation, BOCI is well-positioned to offer its clients a wide range of investment banking services, including securities underwriting, mergers & acquisitions, financial advisory, equity sales & trading, equity derivatives, fixed income, asset management, private equity investments and global commodities.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 42%
Last updated:
For AI agents: llms.txt
Industries BOC International Holdings invests in
Stages BOC International Holdings invests in
Countries BOC International Holdings invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Tong Li
|
|||
Investment Focus
Industry
- Manufacturing 4 (33%)
- Medical 3 (25%)
- Health Care 2 (17%)
- Semiconductor 2 (17%)
- Medical Device 2 (17%)
Stage
- Series A 4 (33%)
- Series B 3 (25%)
- Post-IPO Equity 2 (17%)
- Series C 1 (8%)
- Series E 1 (8%)
Country
- China 11 (92%)
- United States 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Tong Li
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Cruise New Materials
|
Cruise New Materials specializes in the research and development of lightweight, high-temperature thermal protection materials. | $14.7M / Series A / Jul 08, 2026 | |
Haimai Medical
|
Haimai Medical is a platform for tissue engineering and regenerative medicine technology. It focused on the development and manufacture of allogeneic small-caliber tissue-engineered blood vessels suitable for the establishment of chronic renal failure dialysis vascular access, lower extremity arterial trauma blood vessel replacement, lowerextremity atherosclerosis, and coronary heart disease bypass surgery. | Series A / Jun 12, 2026 | |
Genesis Weina
|
Weina World is an equipment manufacturer integrating R&D, design, production and sales focuses on vacuum plasma technology. | Series A / Mar 09, 2026 | |
zrcome
|
zrcome is a high-tech company in precision optics, semiconductor materials and intelligent equipment. | Series B / Aug 18, 2025 | |
Senscomm Semiconductor
|
Senscomm has launched more than 20 products catering to global demand in augmented reality (AR)/ virtual reality (VR), internet of things (IoT), and electric vehicle (EV). | $44.2M / Series A / May 16, 2022 | |
China Resources Vanguard
|
China Resources Vanguard, doing business as China Resources Vanguard Shop or Vanguard, operates the supermarket chains of China Resources. It is the third-largest supermarket chain in Hong Kong. As of December 31, 2014, there are 4866 shops operating in Hong Kong and the mainland Chinese provinces/municipalities of Guangdong, Zhejiang,Jiangsu, Shanghai, Tianjin and Beijing.According to market research firm EuroMonitor's estimates in 2012, China Resources Vanguard supermarket market share in Hong Kong is about 7.8%. Wellcome Hong Kong's market share is about 39.8% and PARKnSHOP Hong Kong's market share is about 33.1%.On August 18, 2013, China Resources Enterprise's supermarket chain Vanguard and British supermarket Tesco signed a "memorandum of understanding", intending to set up a joint venture interest group in mainland China, Hong Kong and Macau, operating hypermarkets, supermarkets, convenience stores, liquor stores and cash and carry businesses. China Resources Enterprise took an 80% share and Tesco took a 20% share. | $400M / Venture - Series Unknown / Apr 21, 2022 | |
Shukun Technology
|
Shukun Technology is a Chinese healthcare company that develops diagnostics systems based on machine learning and artificial intelligence for detecting cardiovascular diseases. The company aims to help improve medical professionals' work efficiency and directly improve the level of diagnosis and treatment in primary hospitals.The company wasfounded in 2017 and headquartered in Beijing, China. | $28.2M / Series B / Jun 15, 2020 | |
Cloudbreak Therapeutics
|
Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Cloudbreak Therapeutics operates a capital efficient business model based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC)Phase II clinical trials and to out-license global rights for Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development. | $25.4M / Series B / Apr 17, 2020 | |
SoYoung Technology
|
The Beijing-based company, which has seen 10 million downloads of its SoYoung app, is trying to enlist 200 clinics and thousands of plastic surgeons to its platform within three years as the industry in China faces less policy restrictions than traditional medical procedures, such as heart operations. It’s trying to tap an aesthetic medicalservices market forecast to double to $11.3 billion over the next five years, according to a prospectus from Union Medical Healthcare Ltd. | $70M / Series E / Sep 04, 2018 | |
G-Banker
|
G-Banker is an online-to-offline platform that facilitates gold trading activities. Customers can purchase, deposit, and extract gold in real time. The company is headquartered in Beijing, China and operates as a B2C company. | $28.3M / Series C / May 09, 2017 | |
| See all 12 investments → | |||
Co-Investors
ABC International
1 deal together
Addor Capital
1 deal together
Beijing Zhongjin Taian Zichan Guanli Youxian Gongsi
1 deal together
Cyber Creation Ventures (CCV)
1 deal together
China Grand Pharmaceutical and Healthcare Holdings
1 deal together
China Merchants Securities
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does BOC International Holdings invest in?
BOC International Holdings invests primarily in Manufacturing, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BOC International Holdings?
Public channels for BOC International Holdings include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BOC International Holdings?
The team at BOC International Holdings includes Tong Li (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
